Bio Rad Laboratories Inc Quick Ratio (BIO) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Bio rad Laboratories Inc   (NYSE: BIO)

Bio Rad Laboratories Inc 's Quick Ratio

BIO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.86 below Bio Rad Laboratories Inc average.

Within Laboratory Analytical Instruments industry 12 other companies have achieved higher Quick Ratio than Bio Rad Laboratories Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1335 to 1898.

Explain Quick Ratio?
How much Cash & cash equivalents BIO´s has?
What are BIO´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BIO/financial-strength
https://api.csimarket.com/api/v1/companies/BIO/fundamentals
https://api.csimarket.com/api/v1/companies/BIO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
BIO Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 213.62 %
Y / Y Cash & cash equivalent Change -40.99 %
Quick Ratio MRQ 0.86
BIO's Total Ranking # 1898
Seq. Current Liabilities Change 0.81 %
Seq. Cash & cash equivalent Change -5.62 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 13
Healthcare Sector # 643
Overall Market # 1898


Quick Ratio Statistics
High Average Low
6.28 2.33 0.92
(Mar 31 2011)   (Jun 30 2026)




Financial Statements
Bio Rad Laboratories Inc 's Current Liabilities $ 969 Millions Visit BIO's Balance sheet
Bio Rad Laboratories Inc 's Cash & cash equivalent $ 837 Millions Visit BIO's Balance sheet
Source of BIO's Sales Visit BIO's Sales by Geography


Cumulative Bio Rad Laboratories Inc 's Quick Ratio

BIO's Quick Ratio for the trailling 12 Months

BIO Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 155.08 %
Y / Y Cash & cash equivalent TTM Growth -20.28 %
Quick Ratio TTM 1.27
Total Ranking TTM # 1616
Seq. Current Liabilities TTM Growth 25.08 %
Seq. Cash & cash equivalent TTM Growth -12.18 %


On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $969.10 millions, cumulative Quick Ratio decreased to 1.27 above the BIO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Laboratory Analytical Instruments industry 21 other companies have achieved higher Quick Ratio than Bio Rad Laboratories Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2747 to 4076.

Explain Quick Ratio?
How much Cash & cash equivalents BIO´s has?
What are BIO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Laboratory Analytical Instruments Industry # 22
Healthcare Sector # 901
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
1.54 0.95 0.6
(Sep 30 2011)   (Sep 30 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Laboratory Analytical Instruments Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Quanterix Corporation  1.51 $ 77.359  Millions$ 51.130  Millions
Nautilus Biotechnology Inc   1.07 $ 10.467  Millions$ 9.758  Millions
Precipio inc   0.90 $ 3.576  Millions$ 3.985  Millions
Bio rad Laboratories Inc   0.86 $ 837.100  Millions$ 969.100  Millions
Bionano Genomics Inc   0.66 $ 8.168  Millions$ 12.307  Millions
Revvity Inc  0.63 $ 592.799  Millions$ 936.977  Millions
Avantor Inc   0.34 $ 464.300  Millions$ 1,369.000  Millions
Waters Corporation  0.27 $ 593.000  Millions$ 2,180.000  Millions
Harvard Bioscience Inc   0.19 $ 4.856  Millions$ 26.127  Millions

Date modified: 2026-11-08T19:11:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.